Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Feb;72(2):1065-71.
doi: 10.1128/IAI.72.2.1065-1071.2004.

Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG

E L Nuermberger  1 , T Yoshimatsu, S Tyagi, W R Bishai, J H Grosset
Affiliations

Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG

E L Nuermberger et al. Infect Immun. 2004 Feb.

Abstract

To develop a murine model of paucibacillary tuberculosis for experimental chemotherapy of latent tuberculosis infection, mice were immunized with viable Mycobacterium bovis BCG by the aerosol or intravenous route and then challenged six weeks later with virulent Mycobacterium tuberculosis. The day after immunization, the counts were 3.71 +/- 0.10 log(10) CFU in the lungs of aerosol-immunized mice and 3.65 +/- 0.11 and 4.93 +/- 0.07 log(10) CFU in the lungs and spleens of intravenously immunized mice, respectively. Six weeks later, the lungs of all BCG-immunized mice had many gross lung lesions and splenomegaly; the counts were 5.97 +/- 0.14 and 3.54 +/- 0.07 log(10) CFU in the lungs and spleens of aerosol-immunized mice, respectively, and 4.36 +/- 0.28 and 5.12 +/- 0.23 log(10) CFU in the lungs and spleens of intravenously immunized mice, respectively. Mice were then aerosol challenged with M. tuberculosis by implanting 2.37 +/- 0.13 log(10) CFU in the lungs. Six weeks after challenge, M. tuberculosis had multiplied so that the counts were 6.41 +/- 0.27 and 4.44 +/- 0.14 log(10) CFU in the lungs and spleens of control mice, respectively. Multiplication of M. tuberculosis was greatly limited in BCG-immunized mice. Six weeks after challenge, the counts were 4.76 +/- 0.24 and 3.73 +/- 0.34 log(10) CFU in the lungs of intravenously immunized and aerosol-immunized mice, respectively. In contrast to intravenously immunized mice, there was no detectable dissemination to the spleen in aerosol-immunized mice. Therefore, immunization of mice with BCG by the aerosol route prior to challenge with a low dose of M. tuberculosis resulted in improved containment of infection and a stable paucibacillary infection. This model may prove to be useful for evaluation of new treatments for latent tuberculosis infection in humans.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Mean spleen weights after immunization and after challenge. IV, intravenous; aero, aerosol.
FIG. 2.
FIG. 2.
Gross appearance of lungs from nonimmunized mice (a, d, and g), intravenously immunized mice (b, e, and h), and aerosol-immunized mice (c, f, and i) at 4 weeks (a to c) and 6 weeks (d to f) after immunization with BCG and at 6 weeks after challenge with M. tuberculosis (g to i).
FIG. 3.
FIG. 3.
Histopathology of the lungs of nonimmunized mice (a and d), intravenously immunized mice (b and e), and aerosol-immunized mice (c and f) 6 weeks after BCG immunization (a to c) and 6 weeks after challenge with M. tuberculosis (d to f). Magnification, ×20.
FIG. 4.
FIG. 4.
Histopathology of the lungs of aerosol-immunized mice 6 weeks after immunization (a and b) and 1 day after challenge with M. tuberculosis (c and d). (a and c) Magnification, ×20; (b and d) magnification, ×200.
See this image and copyright information in PMC

References

    1. Barclay, W. R., W. M. Busey, D. W. Dalgard, R. C. Good, B. W. Janicki, J. E. Kasik, E. Ribi, C. E. Ulrich, and E. Wolinsky. 1973. Protection of monkeys against airborne tuberculosis by aerosol vaccination with bacillus Calmette-Guerin. Am. Rev. Respir. Dis. 107:351-358. - PubMed
    1. Canetti, G. 1955. The tubercle bacillus in the pulmonary lesions of man. Springer-Verlag, New York, N.Y.
    1. Goonetilleke, N. P., H. McShane, C. M. Hannan, R. J. Anderson, R. H. Brookes, and A. V. Hill. 2003. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171:1602-1609. - PubMed
    1. Grosset, J., and B. Ji. 1998. Experimental chemotherapy of mycobacterial diseases, p. 51-97. In P. R. J. Gangadharam and P. A. Jenkins (ed.), Mycobacteria. II. Chemotherapy. Chapman & Hall, New York, N.Y.
    1. Horwitz, M. A., G. Harth, B. J. Dillon, and S. Maslesa-Galic′. 2000. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. USA 97:13853-13858. - PMC - PubMed

Publication types